New Assays Using the Cobas c 111 Analyser

Cobas c 111 clinical chemistry analyzer


RenaSci has recently installed a fully-automated Cobas c 111 clinical chemistry analyser. The Cobas analyser will give us access to the Roche clinical reagent range and will therefore expand the number of assays that we can perform on samples of serum, plasma, whole blood and urine from our animal models of diabetes and obesity. We will be able to perform multiple analyses on the same sample which will reduce the overall amount of plasma required and also increase throughput compared to conventional assays. An additional advantage is that the Cobas c 111 analyser is a widespread industry platform so results can be more readily compared to data obtained using similar equipment. 

We have validated a number of Cobas assays. There is excellent correlation between plasma glucose levels and whole blood HbA1c determined using the Cobas analyser.  

Correlation between HbA1c and plasma glucose levels

The Cobas c 111 analyser is also enabling us to measure LDL-cholesterol ('bad' cholesterol) and HDL-cholesterol ('good' cholesterol) in our animal models of diabetes and obesity for the first time. Rodents typically have lower levels of LDL-C than HDL-C whereas the converse is true in humans. However, we have demonstrated that weight-loss produced by rimonabant or change in diet significantly increases the HDL-C/LDL-C ratio in dietary-induced obese (DIO) mice. This ratio is used clinically as increases in HDL-C relative to LDL-C are associated with health benefits in man. These findings indicate that DIO mice can be used to predict the beneficial effects of different treatments on lipoproteins in the clinic.


HDL-cholesterol and LDL-cholesterol Assays  in Rodents


We will be continuing to expand the number of assays we can offer using the Cobas c 111 analyser. Please click here or contact us for further information.